Combination of GTI-2040 and Cytarabine in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML)

Exclusion Criteria

• •Patients who have had chemotherapy (with the exception of hydroxyurea) or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier. Patients who have received mitomycin C or nitrosurea require a 6 week recovery period before enrollment.
• •Patients who have had prior allogeneic stem cell transplant.
• •Patients may not be receiving any other investigational agents as part of ongoing treatment.
• •Patients with the following abnormal clinical values (unless abnormalities in these parameters are directly attributable to malignancy):
• •* Resting cardiac ejection fraction \< 50%
• •* Serum creatinine \> 1.5 mg/dL
• •* Total bilirubin \> 2x upper limits of normal (ULN) (unless due to Gilbert's syndrome)
• •* aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \> 3x ULN
• •History of allergic reactions attributed to compounds of similar chemical or biologic composition to GTI-2040 or other agents used in the study.
• •Patients who require chronic systemic anticoagulant therapy for medical conditions (e.g., previous history of deep venous thrombosis, atrial fibrillation etc.). Heparin administration to maintain central line patency (i.e. catheter flush) is not an exclusion.
• •Patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection requiring IV antibiotics, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.
• •Serious medical or psychiatric illness that would prevent informed consent or limit survival to \< 4 weeks.
• •Pregnancy or breastfeeding women. The potential for teratogenic effects and other risks for GTI-2040 in nursing infants are unknown. Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry and for the duration of study participation.
• •HIV-positive patients on combination antiretroviral therapy are ineligible because these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated.